Normativa europea
Regulatory news
Regolamento HTA: sono 6 i farmaci oggetto di valutazione clinica congiunta (JCA)
6 products are currently undergoing JCA, at different stages of progress:
Autologous tumor infiltrating lymphocytes: TIL therapy - for the treatment of Melanoma
- Assessor: National High Authority for Health (HAS), France
- Co-assessor: Agency for Health Technology Assessment and Tariff System (AOMiT), Poland
- ATMP, Advanced Therapy Medicinal Product
- *EMA validation reference date: 27/03/2025
_ Tovorafenib - for the treatment of paediatric low-grade glioma
- Assessor: National Centre for Pharmacoeconomics (NCPE), Ireland
- Co-assessor: Institute for Quality and Efficiency in Health Care (IQWiG), Germany
- Orphan Designation
- *EMA validation reference date: 27/03/2025
_ Sasanlimab - for the treatment of bladder cancer
- Assessor: Dutch National Health Care Institute (ZIN), The Netherlands
- Co-assessor: Danish Medicines Council (DkMC), Denmark
- *EMA validation reference date: 22/05/2025
_ Onasemnogene abeparvovec - for the treatment of 5q spinal muscular atrophy (SMA)
- Assessor: National Centre for Pharmacoeconomics (NCPE), Ireland
- Co-Assessor: National High Authority for Health (HAS), France
- ATMP, Advanced Therapy Medicinal Product
- *EMA validation reference date: 22/05/2025
_ Camizestrant - for the treatment of advanced metastatic breast cancer
- Assessor: Federation of Social Insurances (SV) - Austria
- Co-assessor: National Institute for Health and Disability (RIZIV-INAMI) - Belgium
- *EMA validation reference date: 19/06/2025
_ Lurbinectedin - for the treatment of non-small cell lung cancer
- Assessor: Institute for Quality and Efficiency in Health Care (IQWiG), Germany
- Co-assessor: National Authority of Medicines and Health Products (Infarmed), Portugal
Grazie per il tuo feedback!